Prime Medicine, Inc. financial data

Symbol
PRME on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
60 First St., Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 699 % +29.8%
Debt-to-equity 53.4 % +145%
Return On Equity -100 % -6.81%
Return On Assets -65.2 % +15.2%
Operating Margin -6.79K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 131M shares +9.27%
Common Stock, Shares, Outstanding 131M shares +34.7%
Entity Public Float 297M USD -50.8%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 119M shares +30.4%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +30.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.98M USD
Research and Development Expense 155M USD +4.99%
General and Administrative Expense 50.2M USD +15.6%
Operating Income (Loss) -202M USD +1.14%
Nonoperating Income (Expense) 6.59M USD +3.21%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -196M USD +1.14%
Earnings Per Share, Basic -1.65 USD/shares +24.3%
Earnings Per Share, Diluted -1.65 USD/shares +24.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 182M USD +339%
Cash, Cash Equivalents, and Short-term Investments 190M USD +56.5%
Other Assets, Current 14.7M USD +551%
Assets, Current 212M USD +48.2%
Property, Plant and Equipment, Net 24.4M USD +7.7%
Operating Lease, Right-of-Use Asset 47.2M USD +238%
Other Assets, Noncurrent 0 USD -100%
Assets 298M USD +53.5%
Accounts Payable, Current 11.4M USD -41.9%
Employee-related Liabilities, Current 8.98M USD +8.54%
Accrued Liabilities, Current 15.9M USD +12.7%
Contract with Customer, Liability, Current 7.09M USD
Liabilities, Current 38M USD -32.7%
Contract with Customer, Liability, Noncurrent 63.2M USD
Deferred Income Tax Liabilities, Net 134K USD +74%
Operating Lease, Liability, Noncurrent 37.2M USD +753%
Liabilities 144M USD +138%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -687M USD -39.9%
Stockholders' Equity Attributable to Parent 153M USD +15.1%
Liabilities and Equity 298M USD +53.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -67.7M USD -62.9%
Net Cash Provided by (Used in) Financing Activities 157M USD
Net Cash Provided by (Used in) Investing Activities -37M USD -192%
Common Stock, Shares Authorized 775M shares 0%
Common Stock, Shares, Issued 131M shares +34.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 52.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 197M USD +257%
Deferred Tax Assets, Valuation Allowance 180M USD +50.8%
Deferred Tax Assets, Gross 193M USD +56.6%
Operating Lease, Liability 40.8M USD +199%
Payments to Acquire Property, Plant, and Equipment 2.32M USD +16.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -196M USD +0.96%
Lessee, Operating Lease, Liability, to be Paid 206M USD +1316%
Property, Plant and Equipment, Gross 38M USD +26.1%
Operating Lease, Liability, Current 3.61M USD -61%
Lessee, Operating Lease, Liability, to be Paid, Year Two 23.4M USD +781%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.8M USD +104%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +86.7%
Deferred Income Tax Expense (Benefit) 134K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29M USD +2981%
Lessee, Operating Lease, Liability, to be Paid, Year Three 22.9M USD +1262%
Deferred Tax Assets, Operating Loss Carryforwards 61.5M USD +70.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 22.3M USD +3832%
Additional Paid in Capital 840M USD +34.6%
Depreciation, Depletion and Amortization 6.13M USD +31.7%
Share-based Payment Arrangement, Expense 26.1M USD +87.4%